LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Search

Quidel Corp

Lezárt

21.84 3.46

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

20.81

Maximum

22.12

Fő mutatók

By Trading Economics

Munkavállalók

6,600

Ajánlások

By TipRanks

Ajánlások

Semleges

12 hónapos előrejelzés

+45.12% upside

Osztalékok

By Dow Jones

Következő eredményjelentés

2026. máj. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-285M

1.4B

Előző nyitás

18.38

Előző zárás

21.84

Quidel Corp Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. febr. 24. 23:07 UTC

Eredményjelentés

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026. febr. 24. 23:01 UTC

Eredményjelentés

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026. febr. 24. 22:59 UTC

Eredményjelentés

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

2026. febr. 24. 22:42 UTC

Eredményjelentés

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

2026. febr. 24. 22:24 UTC

Felvásárlások, összeolvadások, átvételek

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

2026. febr. 24. 23:48 UTC

Eredményjelentés

OCBC's Fourth-Quarter Net Profit Rose on Higher Non-Interest Income

2026. febr. 24. 23:46 UTC

Piaci beszéd

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

2026. febr. 24. 23:36 UTC

Piaci beszéd

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

2026. febr. 24. 23:30 UTC

Piaci beszéd

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

2026. febr. 24. 23:20 UTC

Piaci beszéd

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

2026. febr. 24. 23:20 UTC

Piaci beszéd

Global Equities Roundup: Market Talk

2026. febr. 24. 23:16 UTC

Eredményjelentés

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

2026. febr. 24. 23:13 UTC

Eredményjelentés

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

2026. febr. 24. 23:12 UTC

Eredményjelentés

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

2026. febr. 24. 23:10 UTC

Eredményjelentés

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

2026. febr. 24. 23:10 UTC

Eredményjelentés

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

2026. febr. 24. 23:08 UTC

Eredményjelentés

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

2026. febr. 24. 23:07 UTC

Eredményjelentés

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

2026. febr. 24. 22:52 UTC

Eredményjelentés

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026. febr. 24. 22:46 UTC

Eredményjelentés

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026. febr. 24. 22:31 UTC

Felvásárlások, összeolvadások, átvételek

Warner Receives New Bid From Paramount -- 3rd Update

2026. febr. 24. 22:29 UTC

Eredményjelentés

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

2026. febr. 24. 22:28 UTC

Eredményjelentés

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

2026. febr. 24. 22:27 UTC

Eredményjelentés

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

2026. febr. 24. 22:27 UTC

Eredményjelentés

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

2026. febr. 24. 22:25 UTC

Eredményjelentés

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

2026. febr. 24. 22:24 UTC

Eredményjelentés

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

2026. febr. 24. 22:23 UTC

Eredményjelentés

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

2026. febr. 24. 22:22 UTC

Eredményjelentés

Woolworths Interim Dividend 45 Australian Cents/Share

2026. febr. 24. 22:22 UTC

Eredményjelentés

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

Társak összehasonlítása

Árváltozás

Quidel Corp Előrejelzés

Célár

By TipRanks

45.12% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 30.75 USD  45.12%

Magas 38 USD

Alacsony 25 USD

5 Wall Street elemző 12 hónapos célárain alapulva a(z)Quidel Corp termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

5 ratings

1

Vétel

3

Tartás

1

Eladás

Pénzügyek

$

Rólunk Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat